Bausch Health Companies (BHC) PT Lowered to $14 at Stifel

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/12/2026

1. ORCL
2. ADBE
3. RH
4. SPY
5. CPRT
6. ACVA
7. SEDG
8. TLT
9. PMTS
10. QQQ

Go back to Bausch Health Companies (BHC) PT Lowered to $14 at Stifel

Bausch Health Announces Third-Quarter 2022 Results

November 3, 2022 7:01 AM EDT

Revenues of $2.046 billion, down 3% reported, up 2% organic basisThird quarter sales improved sequentially, notably Salix, International, and SoltaSuccessful debt exchange offer reduces debt by $2.5 billionCompany updates full year guidance

LAVAL, QC / ACCESSWIRE / November 3, 2022 / Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third-quarter 2022 financial results.

"We are encouraged with the top line... More

Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference

November 1, 2022 8:01 AM EDT

Nine Poster Presentations Include New Analyses of SILIQ and JUBLIA

LAVAL, QC / ACCESSWIRE / November 1, 2022 / - Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, today announced the presentation of nine posters during the Innovations in Dermatology Conference, which takes place Nov. 3-5, 2022, in Las Vegas, Nev. The presentations will feature new data around JUBLIA (efinaconazole) Topical Solution, 10%, and SILIQ (brodalumab) Injection, 210 mg/1.5 mL. There will also be six encore presentations, including analyses of DUOBRII (halobetasol propionate and... More